u/bilal_osei

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.

dose escalation in the trials was slow for a reason

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

incretin effect first, then everything else in this board makes sense

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

Does the effect persist with continued dosing or does tolerance develop?

Same. I sat at 0.5mg for three months because it was working and there was nothing to fix.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

the peripheral and central stories are not in competition

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

compounded is not generic, there is no equivalence claim

Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.

the label on a compounded vial is a legal document, read it

the API source is the question nobody asks and everybody should

Did protein intake change in the same window?

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

comparing reta phase 2 to sema phase 3 is comparing different things

a 503B has to register and report, so there is a paper trail to ask for

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite reg

This is the concept everything else on this board is downstream of.

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

research-use-only material is not approved for human use, full stop